A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity.

Summary: Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon‐like‐peptide‐1 (GLP‐1) receptor agonist could be a treatment option for adolescent obesity. Objective: To investigate the effect of exenatide extended release on body mass index (BMI)‐SDS a...

Descripción completa

Detalles Bibliográficos

Publicado en:	Pediatric Obesity Vol. 15; no. 7; pp. 1 - 12
Autores principales:	Weghuber, D., Forslund, A., Ahlström, H., Alderborn, A., Bergström, K., Brunner, S., Cadamuro, J., Ciba, I., Dahlbom, M., Heu, V., Hofmann, J., Kristinsson, H., Kullberg, J., Ladinger, A., Lagler, F. B., Lidström, M., Manell, H., Meirik, M., Mörwald, K., Roomp, K.
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Wiley-Blackwell Jul2020
Acceso en línea:	Ver este registro en EBSCOhost